BioSpace News Archive

Today, HR Pharmaceuticals, Inc. (HRP) announced the introduction of two ready-to-use intermittent catheter offerings, TruCath Swift™, and TruCath Oasis™, broadening the TruCath® product range to deliver a comprehensive selection of products to meet clinical and individual needs and preferences better.

10x Genomics, Inc., a leader in single cell and spatial biology, announced that the European Unified Patent Court has declined to issue a second preliminary injunction against NanoString Technologies, Inc. based on European Patent 2 794 928 B1.

BioHarvest Sciences Inc, (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) (“BioHarvest” or “the Company”) announces that VINIA®, its flagship nutraceutical product derived from red grape cells, has received its Canadian product license from Health Canada’s Natural and Non-Prescription Health Products Directorate

Mana.bio, a biotechnology company accelerating programmable drug delivery, unveiled its AI-based lipid nanoparticle delivery platform to accelerate the development of nucleic acid-based therapeutics and vaccines.

Leading testing laboratory AlphaBiolabs has just launched the most powerful DNA relationship test available.

American Regent announces the release and availability of Levocarnitine Injection, USP, FDA-approved, “AP” rated, and therapeutically equivalent to Carnitor®.

ALX Oncology Holdings Inc., an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants.

Tempest Therapeutics, Inc. announced the company plans to report new and updated data from the global randomized Phase 1b/2 combination study of TPST-1120 with atezolizumab and bevacizumab in first-line treatment of hepatocellular carcinoma in a premarket press release on Wednesday, October 11, 2023, followed by a webcasted conference call with associated slide presentation at 8:30 a.m. ET on Wednesday, October 11, 2023.

Cumberland Pharmaceuticals Inc. announced a new publication in Antimicrobial Agents and Chemotherapy1 detailing the results of the first clinical study investigating the safety and pharmacokinetics of Vibativ® injection in children 2 to 17 years of age.

Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced participation in the following upcoming investor conferences.